Today Angle Plc (LON:AGLE) has announced results from a prostate cancer research study 21 March 2016 carried out by its KOL partner Barts Cancer Institute (BCI). The final data are yet to be published, but headline results indicate that Parsortix can potentially perform as well as or better than current standard of care in terms of detecting early-stage prostate cancer and assessing its severity, and can do so with a simple blood test. While this will require further clinical studies, it represents a likely second clinical application, in which Parsortix can substantially affect the management of cancer patients.
To read the entire report Please click on the pdf File Below